Status:
TERMINATED
Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)
Lead Sponsor:
Indiana University School of Medicine
Collaborating Sponsors:
National Center for Research Resources (NCRR)
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
21-85 years
Phase:
NA
Brief Summary
This research study plans to evaluate the use of atorvastatin in patients with coronary artery disease given immediately before PCI and whether it will decrease the amount of heart damage after PCI.
Eligibility Criteria
Inclusion
- patients undergoing revascularization for significant coronary artery disease
- age range 21-85 years
Exclusion
- non-STEMI, STEMI
- cancer
- renal failure with creatinine\>3.0mg/dl
- liver cirrhosis
- lymphoproliferative disorder
- pregnancy
- thrombocytopenia\<150'000
- coagulopathy (INR\>1.5)
- abnormal liver function tests
- illicit drug use
- history of statin intolerance
- history of rhabdomyolysis
- planned use of Glycoprotein IIb/IIIa inhibitors during PCI
- current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00979940
Start Date
November 1 2008
End Date
August 1 2014
Last Update
September 22 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Hospital
Indianapolis, Indiana, United States, 46202
2
Wishard Hospital
Indianapolis, Indiana, United States, 46202